Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of medical product maker MedAssets (Nasdaq: MDAS) was miraculously cured today, sending the stock 19% higher.

So what: Revenue grew 50% to $143.7 million and adjusted earnings per share increased a penny to $0.26 per share. Analysts were only expecting revenue of $137.6 million and earnings per share of $0.17, so the results crushed what the "experts" thought.

Now what: When you take out the acquisition of Broadlane, the results aren't quite as eye-popping with adjusted revenue increasing only 2.5%. Nevertheless, beating expectations is always a welcome sight, and with shares trading at just 11 times forward earnings estimates, it looks like there's plenty of upside. MedAssets has now beaten estimates the last three quarters, and I think shares have more room to run.

Interested in more info on MedAssets? Add it to your watchlist by clicking here.